Pancreatic Cancer Research

ResearcherUniversity of Southern DenmarkActive in the last 2 years

Michael Bau Mortensen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7270-5005; OpenAlex author ID A5064447198. Sources: OpenAlex.

Their work

Papers
45 (first author 8, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
110
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 5 papers · 2021: 8 papers · 2022: 1 paper · 2023: 4 papers · 2024: 5 papers · 2025: 5 papers · 2026: 2 papers

Papers 45

  1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for pancreatic cancer peritoneal metastases: A retrospective multicentric study from the ISSPP PIPAC D… Co-author DOI 10.1016/j.ejso.2026.112078↗
  2. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  3. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  4. Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer. Co-author DOI 10.1016/j.prp.2025.156250↗
  5. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  6. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  7. Validity of the Pancreatic Cancer Registry in Southern Denmark. First author DOI 10.61409/a08240545↗
  8. Exploring the prognostic value of circular RNAs in pancreatic ductal adenocarcinoma using genome-wide expression profiling. Co-author DOI 10.1016/j.pan.2024.04.004↗
  9. Prognostic value of margin clearance in total and distal pancreatectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide… Co-author DOI 10.1016/j.prp.2023.155077↗
  10. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Co-author DOI 10.1016/j.radonc.2024.110347↗
  11. RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Last author DOI 10.1515/pp-2024-0001↗
  12. Operation Volume in Pancreatic Cancer Surgery: How Long Will We Keep Looking the Other Way? Co-author DOI 10.20344/amp.21621↗
  13. Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide … Co-author DOI 10.1016/j.hpb.2023.03.016↗
  14. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocar… Co-author DOI 10.1016/j.humpath.2023.11.002↗
  15. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  16. Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials. Co-author DOI 10.3390/curroncol30070499↗
  17. Whole genome sequencing identifies rare genetic variants in familial pancreatic cancer patients. Co-author DOI 10.1111/ahg.12464↗
  18. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  19. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Co-author DOI 10.1016/j.pan.2021.01.025↗
  20. Synchronous detection of pancreatic adenocarcinoma and paraganglioma in a Whipple resection specimen. Co-author DOI 10.1016/j.prp.2021.153590↗
  21. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study. Co-author DOI 10.1080/00365521.2021.1937697↗
  22. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer. Last author DOI 10.1093/bjsopen/zraa028↗
  23. Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients. Co-author DOI 10.1111/cge.14038↗
  24. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. Co-author DOI 10.1136/jclinpath-2020-206607↗
  25. Heritability of familial pancreatic cancer in a Danish national family cohort Co-author DOI 10.21203/rs.3.rs-141845/v1↗
  26. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  27. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  28. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.prp.2020.152925↗
  29. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.prp.2020.152985↗
  30. Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. First author DOI 10.14670/hh-18-201↗
  31. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗
  32. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Co-author DOI 10.1016/j.ejso.2019.05.029↗
  33. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  34. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  35. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. First author DOI 10.3748/wjg.v24.i41.4663↗
  36. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Last author DOI 10.1007/s10585-017-9849-7↗
  37. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Co-author DOI 10.1016/j.ejso.2016.03.011↗
  38. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program. Last author DOI 10.1016/j.pan.2016.03.013↗
  39. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. First author DOI 10.3748/wjg.v22.i9.2678↗
  40. [The impact of desmoplasia and pancreatic stellate cells on pancreatic cancer]. First author PMID 26320589↗
  41. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. First author DOI 10.1016/j.ejca.2012.07.017↗
  42. In reply to Parlak and Topkan. Re: Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer trea… Co-author DOI 10.1016/j.ijrobp.2012.06.001↗
  43. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. First author DOI 10.1016/j.ijrobp.2011.09.008↗
  44. [Danish Pancreatic Cancer Database]. Last author PMID 23079448↗
  45. Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. Co-author DOI 10.3109/0284186x.2011.577095↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sönke Detlefsen · 26 shared papers, 2015–2026 · strength 4.28
  2. Claus Wilki Fristrup · 19 shared papers, 2012–2026 · strength 3.25
  3. Per Pfeiffer · 21 shared papers, 2011–2026 · strength 2.98
  4. Frank Viborg Mortensen · 7 shared papers, 2019–2026 · strength 0.97
  5. Trine Aaquist · 4 shared papers, 2021–2026 · strength 0.81
  6. Michael Friberg Bruun Nielsen · 6 shared papers, 2015–2020 · strength 0.73
  7. Martin Graversen · 4 shared papers, 2017–2025 · strength 0.70
  8. Maiken Thyregod Jøergensen · 5 shared papers, 2016–2022 · strength 0.68
  9. Ove B. Schaffalitzky de Muckadell · 5 shared papers, 2016–2022 · strength 0.68
  10. Ming Tan · 4 shared papers, 2021–2022 · strength 0.61
  11. Carsten Palnæs Hansen · 5 shared papers, 2012–2025 · strength 0.59
  12. Karin de Stricker · 3 shared papers, 2021–2026 · strength 0.57
  13. Jakob Kirkegård · 4 shared papers, 2019–2025 · strength 0.55
  14. Lukas Gammelgaard Rasmussen · 3 shared papers, 2021–2024 · strength 0.53
  15. Britta Weber · 3 shared papers, 2020–2024 · strength 0.49
  16. Jorg H. Kleeff · 3 shared papers, 2020–2026 · strength 0.47
  17. Mathilde Weisz Ejlsmark · 2 shared papers, 2023–2024 · strength 0.41
  18. Uffe Bernchou · 2 shared papers, 2023–2024 · strength 0.41
  19. Ernesto Sparrelid · 2 shared papers, 2025–2026 · strength 0.40
  20. Siri Vreim Ørbeck · 2 shared papers, 2023–2024 · strength 0.39
  21. Cara Manmeet Bhuller · 1 shared paper, 2025 · strength 0.37
  22. Henriette Engberg · 1 shared paper, 2025 · strength 0.37
  23. J. Sven D. Mieog · 2 shared papers, 2016–2024 · strength 0.33
  24. Thilo Hackert · 3 shared papers, 2019–2025 · strength 0.28
  25. Marc G. Besselink · 3 shared papers, 2019–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.